Streetbeat News

Revenues

EL

FXI

Estée Lauder's CFO has forecasted that sales in Mainland China will be flat to down by high single digits for fiscal year 2025. This prediction was made during a conference call.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 2:23 pm

JAZZ

Analysts have provided mixed ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ) over the past three months, with a range of price targets and recommendations. The average price target has decreased by 3.36% to $166.92. Jazz Pharmaceuticals has shown positive revenue growth but lags behind industry peers, with strong net margins and effective debt management.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

ULTA

Ulta Beauty (NASDAQ:ULTA) has been analyzed by 20 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target has decreased by 9.28% to $460.8. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Ulta Beauty's financials show strong revenue growth, net margin, ROE, and ROA, with prudent debt management.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

CAT

Caterpillar (NYSE:CAT) has received mixed analyst ratings over the past three months, with a current average 12-month price target of $349.33, up 2.87% from the previous target. Analysts have adjusted their ratings and price targets in response to market conditions, with some lowering and others raising their expectations. Despite revenue challenges, Caterpillar maintains strong profitability and financial health, though it faces debt management issues.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

VKTX

Viking Therapeutics (NASDAQ:VKTX) has significantly outperformed the market over the past 5 years, with an annualized return of 39.42% and an average annual return of 53.7%. A $100 investment in VKTX 5 years ago would now be worth $817.40, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

HQY

HealthEquity (NASDAQ:HQY) has outperformed the market over the past 10 years with an average annual return of 14.28%, resulting in a $1000 investment growing to $3,772.27. The article highlights the impact of compounded returns over time.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

CDNA

In the last three months, four analysts have rated CareDx (NASDAQ:CDNA) with a bullish outlook. The average 12-month price target has increased by 64.45% to $28.5. Analysts from BTIG, Goldman Sachs, and Craig-Hallum have raised their price targets, reflecting positive sentiment. CareDx, a precision medicine company, has shown a 31.26% revenue growth rate, though it remains below industry averages. The company's financial health is strong, with efficient cost management and a sound debt structure.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

LI

NIO

XPEV

Chinese EV stocks NIO, XPeng, and Li Auto are trading higher due to China's cash-for-clunkers program, which could boost EV sales to over 10 million in 2024. Despite recent stock declines, the program's incentives may drive significant revenue growth.

Portfolio Pulse from Anusuya Lahiri

August 19, 2024 | 1:55 pm

RSSS

Research Solutions, Inc. (NASDAQ:RSSS) reported preliminary Q4 2024 revenue of $12.1M, a 22% increase YoY, and expects FY24 revenue of $44.6M. The company anticipates record revenue and income from operations, with strong cash flow. Platform revenue and ARR showed significant growth, driven by the Scite acquisition.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 1:07 pm

VCIG

VCI Global's shares are rising following a year-over-year increase in H1 revenue and the announcement of a $10 million share repurchase program.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 1:03 pm